Journal Article FZJ-2017-05584

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs

 ;  ;  ;  ;

2017
Elsevier New York, NY [u.a.]

European journal of pharmaceutical sciences 107, 203-207 () [10.1016/j.ejps.2017.07.015]

This record in other databases:      

Please use a persistent id in citations:   doi:

Abstract: The aggregation of the amyloid β protein (Aβ) plays an important role in the pathology of Alzheimer's disease. Previously, we have developed the all-d-enantiomeric peptide D3, which is able to eliminate neurotoxic Aβ oligomers in vitro and improve cognition in a transgenic Alzheimer's disease mouse model in vivo even after oral administration. d-Peptides are expected to be more resistant against enzymatic proteolysis compared to their l-enantiomeric equivalents, and indeed, a pharmacokinetic study with tritiated D3 revealed the oral bioavailability to be about 58%. To further investigate the underlying properties, we examined the stability of D3 in comparison to its corresponding all-l-enantiomeric mirror image l-D3 in media simulating the gastrointestinal tract, blood and liver. Potential metabolization was followed by reversed-phase high-performance liquid chromatography. In simulated gastric fluid, D3 remained almost completely stable (89%) within 24 h, while 70% of l-D3 was degraded within the same time period. Notably, in simulated intestinal fluid, D3 also remained stable (96%) for 24 h, whereas l-D3 was completely metabolized within seconds. In human plasma and human liver microsomes, l-D3 was metabolized several hundred times faster than D3. The remarkably high stability may explain the high oral bioavailability seen in previous studies allowing oral administration of the drug candidate. Thus, all-d-enantiomeric peptides may represent a promising new compound class for drug development.

Classification:

Contributing Institute(s):
  1. Strukturbiochemie (ICS-6)
  2. Analytik (ZEA-3)
Research Program(s):
  1. 553 - Physical Basis of Diseases (POF3-553) (POF3-553)

Appears in the scientific report 2017
Database coverage:
Medline ; Embargoed OpenAccess ; BIOSIS Previews ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > IBI > IBI-7
Institute Collections > ZEA > ZEA-3
Workflow collections > Public records
ICS > ICS-6
Publications database
Open Access

 Record created 2017-07-31, last modified 2021-01-29


Published on 2017-07-12. Available in OpenAccess from 2018-07-12.:
Download fulltext PDF Download fulltext PDF (PDFA)
(additional files)
External link:
Download fulltextFulltext by OpenAccess repository
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)